These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2726917)

  • 1. Effects of 9-amino-1,2,3,4-tetrahydroacridine (THA), a potential drug for treatment of Alzheimer's disease, on the physical state of human erythrocyte membranes.
    Palmieri DA; Butterfield DA
    Prog Clin Biol Res; 1989; 292():419-24. PubMed ID: 2726917
    [No Abstract]   [Full Text] [Related]  

  • 2. Spin-labelling studies of the interaction of 9-amino-1,2,3,4-tetrahydroacridine (THA), a proposed drug for the treatment of Alzheimer's disease, with erythrocyte membranes.
    Butterfield DA; Palmieri DA
    Free Radic Res Commun; 1990; 9(3-6):361-6. PubMed ID: 2167274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity investigation of the alteration of the physical state of the skeletal network of proteins in human erythrocyte membranes induced by 9-amino-1,2,3,4-tetrahydroacridine.
    Palmieri DA; Butterfield DA
    Biochim Biophys Acta; 1990 May; 1024(2):285-8. PubMed ID: 2354181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current.
    Drukarch B; Kits KS; Van der Meer EG; Lodder JC; Stoof JC
    Eur J Pharmacol; 1987 Sep; 141(1):153-7. PubMed ID: 2444444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
    Mesulam MM; Geula C; Morán MA
    Ann Neurol; 1987 Dec; 22(6):683-91. PubMed ID: 3435078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological alterations in erythrocyte membranes induced by 9-amino-1,2,3,4-tetrahydroacridine and 9-aminoacridine.
    Palmieri DA; Jacob RJ; Butterfield DA
    Biochem Biophys Res Commun; 1989 Sep; 163(3):1351-5. PubMed ID: 2783139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximizing function in Alzheimer's disease: what role for tacrine?
    Smucker WD
    Am Fam Physician; 1996 Aug; 54(2):645-52. PubMed ID: 8701842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple actions of THA on cholinergic neurotransmission in Alzheimer brains.
    Nordberg A; Nilsson-Håkansson L; Adem A; Lai Z; Winblad B
    Prog Clin Biol Res; 1989; 317():1169-78. PubMed ID: 2557636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane-altering effects of velnacrine and N-methylacridinium: relevance to tacrine and Alzheimer's disease.
    Butterfield DA; Rangachari A
    Biochem Biophys Res Commun; 1992 Jun; 185(2):596-603. PubMed ID: 1319141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THA increases action potential duration of central histamine neurons in vitro.
    Reiner PB; McGeer EG
    Eur J Pharmacol; 1988 Oct; 155(3):265-70. PubMed ID: 3148476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tacrine in Alzheimer's disease].
    López de Munain A
    Rev Neurol; 1997 Jul; 25 Suppl 1():S70-2. PubMed ID: 9280671
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tetrahydroaminoacridine: a promising 'therapy' for Alzheimer's disease?].
    Drukarch B; Stoof JC
    Ned Tijdschr Geneeskd; 1988 Oct; 132(40):1833-5. PubMed ID: 3185771
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effects of polymethylene derivatives of 4-aminopyridine on functional properties of hippocampal neurons].
    Chepkova AN; Doreuli NV; Skrebitskiĭ VG
    Biull Eksp Biol Med; 1989 Oct; 108(10):449-52. PubMed ID: 2557101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrine. Alzheimer's disease and the cholinergic theory. A critical review and results of a new therapy.
    Boller F; Orgogozo JM
    Neurologia; 1995 May; 10(5):194-9. PubMed ID: 7619536
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical pharmacology of tetrahydroaminoacridine: a possible therapeutic agent Alzheimer's disease.
    Kumar V; Becker RE
    Int J Clin Pharmacol Ther Toxicol; 1989 Oct; 27(10):478-85. PubMed ID: 2684868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of 9-amino-1,2,3,4-tetrahydroacridine (THA) on the potassium current of rabbit sinoatrial node.
    Kotake H; Hisatome I; Matsuoka S; Miyakoda H; Hasegawa J; Mashiba H
    Cardiovasc Res; 1990 Jan; 24(1):42-6. PubMed ID: 2328513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrine therapy for the dementia of Alzheimer's disease.
    Manning FC
    Am Fam Physician; 1994 Sep; 50(4):819-26. PubMed ID: 8079912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
    Shao D; Zou C; Luo C; Tang X; Li Y
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4639-42. PubMed ID: 15324879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of diisopropylfluorophosphate (DFP)-induced lethality by meptazinol and 9-amino-tetrahydroacridine (THA) in the mouse.
    Galli A; Mazri A; Mori F; Cecchini L; Lucherini M
    Acta Physiol Hung; 1990; 75 Suppl():125-6. PubMed ID: 2371839
    [No Abstract]   [Full Text] [Related]  

  • 20. [Use of cholinesterase inhibitors in Alzheimer disease].
    Sampalmieri M; Troiani MP; Servi M
    Clin Ter; 1993 Dec; 143(6):549-52. PubMed ID: 8306579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.